# US 8,785,490 B2 · Compounds for treating disease, for administering, and for pharmaceutical compositions > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,785,490 B2 - Document ID: US8785490B2 - Status: Granted - Kind: B2 - Application number: 13/639,864 - Filed: 2011-04-08 - Published: 2013-03-07 - Granted: 2014-07-22 - Earliest claimed: 2010-04-09 - Assignees: University of Louisville Research Foundation, Inc. - Applicants: John O. Trent; Jason B. Meier; Kelby B. Napier - Inventors: John O. Trent; Jason B. Meier; Kelby B. Napier - Web page: https://patentgrep.com/patent/US8785490B2 ## CPC - C07D 403/12: linked by a chain containing hetero atoms as chain links - A61K 31/132: having two or more amino groups, e.g. spermidine, putrescine - A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin - A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide - A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin - A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole - A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles - A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil - A61K 31/4196: 1,2,4-Triazoles - A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone - A61K 31/47: Quinolines; Isoquinolines - A61K 31/472: Non-condensed isoquinolines, e.g. papaverine - A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines - A61K 31/4965: Non-condensed pyrazines - A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine - A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 13/12: of the kidneys - A61P 31/18: for HIV - A61P 31/22: for herpes viruses - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61P 35/04: specific for metastasis - C07D 217/24: Oxygen atoms - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Some embodiments of this invention include methods for treating disease and methods for administering a compound of Formula (I). In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of Formula (I). Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I). ## Claims ### Claim 1 A method for treating a CXCR4 expressing cancer in an animal comprising administering a composition comprising a compound of Formula (I) to the animal, wherein the CXCR4 expressing cancer is breast cancer, ovarian cancer, colon cancer, melanoma, squamous cell carcinoma, chronic lymphocytic leukemia, rectal cancer, lung cancer, or prostate cancer, and the compound of Formula (I) is selected from the group consisting of ### Claim 2 (depends on 1) The method of claim 1, further comprising identifying an animal with the CXCR4 expressing cancer. ### Claim 3 (depends on 1) The method of claim 1, wherein the compound is selected from the group consisting of I-38, I-47 to I-52, and I-54 to I-58. ### Claim 4 (depends on 1) The method of claim 1, wherein the CXCR4 expressing cancer comprises a cancerous tumor. ### Claim 5 (depends on 1) The method of claim 1, wherein the CXCR4 expressing cancer comprises a cancerous tumor and the treating results in a decrease in the size of the cancerous tumor. ### Claim 6 (depends on 1) The method of claim 1, wherein the CXCR4 expressing cancer comprises a cancerous tumor and the treating results in a decrease in the number of cancerous tumors. ### Claim 7 (depends on 1) The method of claim 1, wherein the CXCR4 expressing cancer is metastasized. ### Claim 8 (depends on 1) The method of claim 1, wherein the CXCR4 expressing cancer is metastasized to the breasts, ovaries, colon, rectum, lungs, or prostate. ### Claim 9 (depends on 1) The method of claim 1, wherein the CXCR4 expressing cancer is breast cancer or lung cancer. ### Claim 10 (depends on 1) The method of claim 1, wherein the administering is part of an adjuvant treatment. ### Claim 11 (depends on 1) The method of claim 1, wherein the compound of Formula (I) inhibits chemotaxis. ### Claim 12 (depends on 1) The method of claim 1, wherein the compound of Formula (I) inhibits intracellular calcium mobilization. ### Claim 13 (depends on 1) The method of claim 1, wherein the treating results in at least one of modulation of tumor cell migration or modulation of homing of the neoplastic cells. ### Claim 14 (depends on 1) The method of claim 1, wherein the compound of Formula (I) modulates activity of CXCR4. ### Claim 15 (depends on 1) The method of claim 1, wherein the animal is a mammal. ### Claim 16 (depends on 1) The method of claim 1, wherein the animal is a human. ### Claim 17 (depends on 1) The method of claim 1, wherein the administering is by an oral route or by a parenteral route. ### Claim 18 (depends on 1) The method of claim 1, wherein the treating comprises treating metastasis of breast cancer, ovarian cancer, colon cancer, melanoma, chronic lymphocytic leukemia, rectal cancer, lung cancer, or prostate cancer. ### Claim 19 (depends on 1) The method of claim 1, wherein the compound of Formula (I) is I-38.